The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma.

Dysregulated metabolism is a hallmark of cancer that manifests through alterations in bioenergetic and biosynthetic pathways to enable tumor cell proliferation and survival. Tumor cells exhibit high rates of glycolysis, a phenomenon known as the Warburg effect, and an increase in glutamine consumpti...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ethan Emberley, Alison Pan, Jason Chen, Rosalyn Dang, Matt Gross, Tony Huang, Weiqun Li, Andrew MacKinnon, Devansh Singh, Natalija Sotirovska, Susanne M Steggerda, Tracy Wang, Francesco Parlati
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/7d63fa6070aa459a8560bca0f0b6c492
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7d63fa6070aa459a8560bca0f0b6c492
record_format	dspace
spelling	oai:doaj.org-article:7d63fa6070aa459a8560bca0f0b6c4922021-12-02T20:04:30ZThe glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma.1932-620310.1371/journal.pone.0259241https://doaj.org/article/7d63fa6070aa459a8560bca0f0b6c4922021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0259241https://doaj.org/toc/1932-6203Dysregulated metabolism is a hallmark of cancer that manifests through alterations in bioenergetic and biosynthetic pathways to enable tumor cell proliferation and survival. Tumor cells exhibit high rates of glycolysis, a phenomenon known as the Warburg effect, and an increase in glutamine consumption to support the tricarboxylic acid (TCA) cycle. Renal cell carcinoma (RCC) tumors express high levels of glutaminase (GLS), the enzyme required for the first step in metabolic conversion of glutamine to glutamate and the entry of glutamine into the TCA cycle. We found that RCC cells are highly dependent on glutamine for proliferation, and this dependence strongly correlated with sensitivity to telaglenstat (CB-839), an investigational, first-in-class, selective, orally bioavailable GLS inhibitor. Metabolic profiling of RCC cell lines treated with telaglenastat revealed a decrease in glutamine consumption, which was concomitant with a decrease in the production of glutamate and other glutamine-derived metabolites, consistent with GLS inhibition. Treatment of RCC cells with signal transduction inhibitors everolimus (mTOR inhibitor) or cabozantinib (VEGFR/MET/AXL inhibitor) in combination with telaglenastat resulted in decreased consumption of both glucose and glutamine and synergistic anti-proliferative effects. Treatment of mice bearing Caki-1 RCC xenograft tumors with cabozantinib plus telaglenastat resulted in reduced tumor growth compared to either agent alone. Enhanced anti-tumor activity was also observed with the combination of everolimus plus telaglenastat. Collectively, our results demonstrate potent, synergistic, anti-tumor activity of telaglenastat plus signal transduction inhibitors cabozantinib or everolimus via a mechanism involving dual inhibition of glucose and glutamine consumption.Ethan EmberleyAlison PanJason ChenRosalyn DangMatt GrossTony HuangWeiqun LiAndrew MacKinnonDevansh SinghNatalija SotirovskaSusanne M SteggerdaTracy WangFrancesco ParlatiPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 11, p e0259241 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Ethan Emberley Alison Pan Jason Chen Rosalyn Dang Matt Gross Tony Huang Weiqun Li Andrew MacKinnon Devansh Singh Natalija Sotirovska Susanne M Steggerda Tracy Wang Francesco Parlati The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma.
description	Dysregulated metabolism is a hallmark of cancer that manifests through alterations in bioenergetic and biosynthetic pathways to enable tumor cell proliferation and survival. Tumor cells exhibit high rates of glycolysis, a phenomenon known as the Warburg effect, and an increase in glutamine consumption to support the tricarboxylic acid (TCA) cycle. Renal cell carcinoma (RCC) tumors express high levels of glutaminase (GLS), the enzyme required for the first step in metabolic conversion of glutamine to glutamate and the entry of glutamine into the TCA cycle. We found that RCC cells are highly dependent on glutamine for proliferation, and this dependence strongly correlated with sensitivity to telaglenstat (CB-839), an investigational, first-in-class, selective, orally bioavailable GLS inhibitor. Metabolic profiling of RCC cell lines treated with telaglenastat revealed a decrease in glutamine consumption, which was concomitant with a decrease in the production of glutamate and other glutamine-derived metabolites, consistent with GLS inhibition. Treatment of RCC cells with signal transduction inhibitors everolimus (mTOR inhibitor) or cabozantinib (VEGFR/MET/AXL inhibitor) in combination with telaglenastat resulted in decreased consumption of both glucose and glutamine and synergistic anti-proliferative effects. Treatment of mice bearing Caki-1 RCC xenograft tumors with cabozantinib plus telaglenastat resulted in reduced tumor growth compared to either agent alone. Enhanced anti-tumor activity was also observed with the combination of everolimus plus telaglenastat. Collectively, our results demonstrate potent, synergistic, anti-tumor activity of telaglenastat plus signal transduction inhibitors cabozantinib or everolimus via a mechanism involving dual inhibition of glucose and glutamine consumption.
format	article
author	Ethan Emberley Alison Pan Jason Chen Rosalyn Dang Matt Gross Tony Huang Weiqun Li Andrew MacKinnon Devansh Singh Natalija Sotirovska Susanne M Steggerda Tracy Wang Francesco Parlati
author_facet	Ethan Emberley Alison Pan Jason Chen Rosalyn Dang Matt Gross Tony Huang Weiqun Li Andrew MacKinnon Devansh Singh Natalija Sotirovska Susanne M Steggerda Tracy Wang Francesco Parlati
author_sort	Ethan Emberley
title	The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma.
title_short	The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma.
title_full	The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma.
title_fullStr	The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma.
title_full_unstemmed	The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma.
title_sort	glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/7d63fa6070aa459a8560bca0f0b6c492
work_keys_str_mv	AT ethanemberley theglutaminaseinhibitortelaglenastatenhancestheantitumoractivityofsignaltransductioninhibitorseverolimusandcabozantinibinmodelsofrenalcellcarcinoma AT alisonpan theglutaminaseinhibitortelaglenastatenhancestheantitumoractivityofsignaltransductioninhibitorseverolimusandcabozantinibinmodelsofrenalcellcarcinoma AT jasonchen theglutaminaseinhibitortelaglenastatenhancestheantitumoractivityofsignaltransductioninhibitorseverolimusandcabozantinibinmodelsofrenalcellcarcinoma AT rosalyndang theglutaminaseinhibitortelaglenastatenhancestheantitumoractivityofsignaltransductioninhibitorseverolimusandcabozantinibinmodelsofrenalcellcarcinoma AT mattgross theglutaminaseinhibitortelaglenastatenhancestheantitumoractivityofsignaltransductioninhibitorseverolimusandcabozantinibinmodelsofrenalcellcarcinoma AT tonyhuang theglutaminaseinhibitortelaglenastatenhancestheantitumoractivityofsignaltransductioninhibitorseverolimusandcabozantinibinmodelsofrenalcellcarcinoma AT weiqunli theglutaminaseinhibitortelaglenastatenhancestheantitumoractivityofsignaltransductioninhibitorseverolimusandcabozantinibinmodelsofrenalcellcarcinoma AT andrewmackinnon theglutaminaseinhibitortelaglenastatenhancestheantitumoractivityofsignaltransductioninhibitorseverolimusandcabozantinibinmodelsofrenalcellcarcinoma AT devanshsingh theglutaminaseinhibitortelaglenastatenhancestheantitumoractivityofsignaltransductioninhibitorseverolimusandcabozantinibinmodelsofrenalcellcarcinoma AT natalijasotirovska theglutaminaseinhibitortelaglenastatenhancestheantitumoractivityofsignaltransductioninhibitorseverolimusandcabozantinibinmodelsofrenalcellcarcinoma AT susannemsteggerda theglutaminaseinhibitortelaglenastatenhancestheantitumoractivityofsignaltransductioninhibitorseverolimusandcabozantinibinmodelsofrenalcellcarcinoma AT tracywang theglutaminaseinhibitortelaglenastatenhancestheantitumoractivityofsignaltransductioninhibitorseverolimusandcabozantinibinmodelsofrenalcellcarcinoma AT francescoparlati theglutaminaseinhibitortelaglenastatenhancestheantitumoractivityofsignaltransductioninhibitorseverolimusandcabozantinibinmodelsofrenalcellcarcinoma AT ethanemberley glutaminaseinhibitortelaglenastatenhancestheantitumoractivityofsignaltransductioninhibitorseverolimusandcabozantinibinmodelsofrenalcellcarcinoma AT alisonpan glutaminaseinhibitortelaglenastatenhancestheantitumoractivityofsignaltransductioninhibitorseverolimusandcabozantinibinmodelsofrenalcellcarcinoma AT jasonchen glutaminaseinhibitortelaglenastatenhancestheantitumoractivityofsignaltransductioninhibitorseverolimusandcabozantinibinmodelsofrenalcellcarcinoma AT rosalyndang glutaminaseinhibitortelaglenastatenhancestheantitumoractivityofsignaltransductioninhibitorseverolimusandcabozantinibinmodelsofrenalcellcarcinoma AT mattgross glutaminaseinhibitortelaglenastatenhancestheantitumoractivityofsignaltransductioninhibitorseverolimusandcabozantinibinmodelsofrenalcellcarcinoma AT tonyhuang glutaminaseinhibitortelaglenastatenhancestheantitumoractivityofsignaltransductioninhibitorseverolimusandcabozantinibinmodelsofrenalcellcarcinoma AT weiqunli glutaminaseinhibitortelaglenastatenhancestheantitumoractivityofsignaltransductioninhibitorseverolimusandcabozantinibinmodelsofrenalcellcarcinoma AT andrewmackinnon glutaminaseinhibitortelaglenastatenhancestheantitumoractivityofsignaltransductioninhibitorseverolimusandcabozantinibinmodelsofrenalcellcarcinoma AT devanshsingh glutaminaseinhibitortelaglenastatenhancestheantitumoractivityofsignaltransductioninhibitorseverolimusandcabozantinibinmodelsofrenalcellcarcinoma AT natalijasotirovska glutaminaseinhibitortelaglenastatenhancestheantitumoractivityofsignaltransductioninhibitorseverolimusandcabozantinibinmodelsofrenalcellcarcinoma AT susannemsteggerda glutaminaseinhibitortelaglenastatenhancestheantitumoractivityofsignaltransductioninhibitorseverolimusandcabozantinibinmodelsofrenalcellcarcinoma AT tracywang glutaminaseinhibitortelaglenastatenhancestheantitumoractivityofsignaltransductioninhibitorseverolimusandcabozantinibinmodelsofrenalcellcarcinoma AT francescoparlati glutaminaseinhibitortelaglenastatenhancestheantitumoractivityofsignaltransductioninhibitorseverolimusandcabozantinibinmodelsofrenalcellcarcinoma
_version_	1718375551574474752

The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma.

Ejemplares similares